Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-NIMP in Relapsed Aggressive Lymphomas
NCT00842595Phase 2Completed
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Dec 2003
- Primary completion
- Nov 2009
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone in diffuse large B-cell lymphoma (DLBCL), sponsored by French Innovative Leukemia Organisation. Primary endpoint: Complete Remission Rate. Started Dec 2003; status: completed.
02
Drugs
rituximabvinorelbineifosfamidemitoxantroneprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00842595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00842595.